Clinical Trial Update: Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the injection burden, adverse events, disease activity, and long-term visual acuity preservation of Surabgene Lomparvovec in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Surabgene Lomparvovec

Snippet

Sponsor: AbbVie | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: RECRUITING